MilliporeSigma Opens New €290 Million Biosafety Testing Facility in Rockville, Maryland, USA October 9, 2024 Burlington, Massachusetts, October 9, 2024 – MilliporeSigma, the U.S. and Canada Life Science business of [….]
Join the Kymanox CARES Team in Rockville, MD for a night of brews, bites, and positivity as they raise money for Tommy’s Pantry. RSVP/DONATE: [email protected] Make sure to Follow Kymanox [….]
Please join us on Tuesday, June 4th from 6-8pm for our bioscience-focused networking event series designed to highlight the area’s unique life science ecosystem and to promote interactions between its [….]
Connecting with peers in your career field is essential for networking, understanding job opportunities, receiving and giving work advice, and feeling connected to the women-in-science community. Traditional evening networking meetings [….]
We are looking to fill full-time opportunities in multiple groups such as: Must successfully complete an employment-related drug screen, complete a favorable background check, and sign and agree to the [….]
TEDCO’s Q1 Investments Top $2.7M to Fuel Innovation Across Maryland’s Diverse Startup Ecosystem TEDCO deployed more than $2.7M of diverse investments in Maryland’s burgeoning technology and biotech sectors, driving innovation [….]
Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today announced it has entered an agreement to lease new laboratory and office space, commencing in June 2023, to complement the development of the Company’s lead drug candidates and accelerate broader diagnostic capabilities on predictive biomarkers. The new laboratory space, located in Gaithersburg, Maryland, is located within the Maryland Biotech Corridor.
REGENXBIO Inc. (Nasdaq: RGNX) today announced results from a Phase II bridging study evaluating the pharmacodynamics, safety and efficacy of RGX-314, a potential one-time therapy delivered subretinally using cGMP material produced by the company’s NAVXpress™ bioreactor platform process. The data is being presented at the Angiogenesis, Exudation, and Degeneration 2023 Conference by Charles C. Wykoff, M.D., PhD., Director of Research at Retina Consultants of Texas; Chairman of Research, Retina Consultants of America; and Deputy Chair of Ophthalmology for the Blanton Eye Institute, Houston Methodist Hospital.
MaxCyte, Inc. (Nasdaq: MXCT) (LSE: MXCT), a leading commercial cell-engineering company providing enabling platform technologies to advance innovative cell-based research, as well as next-generation cell therapeutic discovery, development and commercialization, today announced the signing of a strategic platform license (SPL) with Catamaran Bio, Inc., a biotechnology company developing novel, off the-shelf chimeric antigen receptor (CAR)-NK cell therapies to treat a broad range of cancers, with a primary focus on solid tumors.
MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research, and Curamys, a South Korean biotechnology company that develops cell & gene therapy using cell fusion technology to treat rare intractable diseases, including Duchenne muscular dystrophy and amyotrophic lateral sclerosis, today announced the signing of a strategic platform license (SPL).
